Back to top

Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Pfizer (PFE - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of PFE and the rest of the Medical group's stocks.

Pfizer is one of 816 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. PFE is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for PFE's full-year earnings has moved 0.39% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the latest available data, PFE has gained about 18.89% so far this year. At the same time, Medical stocks have gained an average of 0.71%. This means that Pfizer is performing better than its sector in terms of year-to-date returns.

To break things down more, PFE belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #32 in the Zacks Industry Rank. On average, this group has gained an average of 6.91% so far this year, meaning that PFE is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on PFE as it attempts to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Pfizer Inc. (PFE) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in